Mechanical Thrombectomy For Large Vessel Occlusion Between 6 And 24 Hours: Outcome Comparison Of Defuse-3/Dawn Eligible Versus Non-Eligible Patients

The DEFUSE-3 and DAWN trials showed that mechanical thrombectomy (MT) improves the outcome of selected patients with large vessel occlusions in the anterior circulation (LVO) up to 24 hours of stroke onset. However, it is unknown whether only those patients fulfilling the trial inclusion criteria benefit, or whether benefit is seen in a broader range of patients presenting between 6 and 24 hours.; We determined whether fulfilling the DEFUSE-3 and DAWN selection criteria affects outcomes in MT patients in clinical practice.; We reviewed adult patients with LVO treated with MT between 6 and 24 hours after stroke onset at five Swiss stroke centers between 2014 and 2021. We compared two groups: (1) patients who satisfied neither DEFUSE-3 nor DAWN criteria (NDND); and (2) those who satisfied DEFUSE-3 or DAWN criteria (DOD). We used logistic regression to examine the impact of trial eligibility on two safety outcomes (symptomatic intracranial hemorrhage [sICH] and all-cause mortality at three months) and two efficacy outcomes (modified Rankin Score [mRS] shift toward lower categories and mRS of 0-2 at three months).; Of 174 patients who received MT, 102 (59%) belonged to the NDND group. Rates of sICH were similar between the NDND group and the DOD group (3% vs. 4%, p=1.00). Multivariable regression revealed no differences in 3-month all-cause mortality (aOR 2.07, 95%CI 0.64-6.84, p=0.23) or functional outcomes (mRS shift: acOR 0.81, 95%CI 0.37-1.79, p=0.60; mRS 0-2: aOR 0.91, 95%CI 0.31-2.57, p=0.85).; Among adult patients with LVO treated with MT between 6 and 24 hours, safety and efficacy outcomes were similar between DEFUSE-3/DAWN eligible vs. ineligible patients. Our data provide a compelling rationale for randomized trials with broader inclusion criteria for MT.